by sd2040@sdconsulting.services | Jun 17, 2022 | Industry News
Summary: On June 2, 2022, the FDA’s Office of Prescription Drug Promotion (OPDP) issued an Untitled Letter to Althera Pharmaceuticals, Inc., for an HCP-facing promotional material about their LDL-C reducing combination statin drug, ROSZET (rosuvastatin and...
